 Total revenue of 1.7M reported for Q2 Reported sales of approximately 3,500 consumable treatment tips - a 42 unit increase quarter-over-quarter Pivotal SUI PURSUIT trial enrollment on-track for completion in early Q4 Potential long-term reimbursement pathway established with new Category III CPT code ENGLEWOOD, CO ACCESSWIRE August 12, 2021 Viveve Medical, Inc. NASDAQ:VIVE, a medical technology company focused on womens intimate health, today reported financial results for the quarter ended June 30, 2021, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today. During the second quarter of 2021, Viveve continued its focus on advancing its stress urinary incontinence SUI clinical development program. 